Security Snapshot

Janux Therapeutics, Inc. - Common Stock, par value $0.001 per share (JANX) Institutional Ownership

CUSIP: 47103J105

13F Institutional Holders and Ownership History from Q2 2021 to Q2 2026

Latest Period

Q2 2026

Institutions Reporting

192

Shares (Excl. Options)

60,725,969

Price

$15.36

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0%
Share change
+5,096,391
Value change
+$84,600,524
Number of holders
192
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
60,419,303
SEC-reported price per share
$15.62
Insider filing price
$15.62
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors

Key facts

  • JANX - Janux Therapeutics, Inc. - Common Stock, par value $0.001 per share is tracked under CUSIP 47103J105.
  • 192 institutions reported positions in Q2 2026.
  • 9 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 188 to 192 between Q1 2026 and Q2 2026.
  • SEC-reported value moved from $827,823,706 to $932,420,447.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 192 institutions filings for Q2 2026.

Open SEC evidence

Security key

47103J105

Latest holder period

Q2 2026

13F holders

192

13D/G owners

9

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
9
Security
JANX
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
RA CAPITAL MANAGEMENT, L.P. 20% $383,922,060 11,971,377 RA Capital Management, L.P. 06 Mar 2025
BlackRock, Inc. 6.7% +17% $62,952,300 +$11,562,900 4,098,457 +23% BlackRock, Inc. 30 Jun 2026
Prosight Management, LP 5.3% $43,569,636 3,157,220 W. Lawrence Hawkins 03 Feb 2026
Paradigm Biocapital Advisors LP 4.9% -18% $73,444,489 -$14,982,559 2,920,258 -17% Paradigm BioCapital Advisors LP 30 Jun 2025
FMR LLC 4.2% -27% $35,246,558 -$13,575,574 2,535,724 -28% FMR LLC 31 Mar 2026
Adage Capital Management, L.P. 4.3% -21% $63,503,750 -$13,499,262 2,525,000 -18% Adage Capital Management, L.P. 30 Jun 2025
STATE STREET CORP 4.1% -38% $34,249,836 -$19,320,083 2,464,017 -36% STATE STREET CORPORATION 31 Mar 2026
Point72 Asset Management, L.P. 3.3% -34% $32,200,468 -$17,376,140 1,993,837 -35% Point72 Asset Management, L.P. 30 Jun 2026
Janus Henderson Group Ltd. 0.3% -94% $2,781,498 -$64,990,507 172,229 -96% JANUS HENDERSON GROUP Ltd. 30 Jun 2026

As of 30 Jun 2026, 192 institutional investors reported holding 60,725,969 shares of Janux Therapeutics, Inc. - Common Stock, par value $0.001 per share (JANX). This represents 101% of the company’s total 60,419,303 outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
84%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
RA CAPITAL MANAGEMENT, L.P. 19% 11,189,693 0% 1.5% $171,873,684
BlackRock, Inc. 10% 6,134,667 +13% 0% $94,228,481
Prosight Management, LP 6.3% 3,804,481 +7.2% 10% $58,436,828
STATE STREET CORP 5% 3,004,899 +22% 0% $46,155,249
FMR LLC 4% 2,412,825 -4.8% 0% $37,060,986
FEDERATED HERMES, INC. 3.9% 2,352,927 +4241% 0.05% $36,140,959
Point72 Asset Management, L.P. 3.3% 1,993,837 +72% 0.05% $30,625,336
VANGUARD CAPITAL MANAGEMENT LLC 3.1% 1,857,351 +2.5% 0% $28,528,911
TCG Crossover Management, LLC 3% 1,789,617 0% 0.66% $27,488,517
Alyeska Investment Group, L.P. 2.7% 1,647,140 +2.9% 0.07% $25,300,070
WELLINGTON MANAGEMENT GROUP LLP 2.5% 1,507,360 -5.7% 0% $23,153,049
VANGUARD PORTFOLIO MANAGEMENT LLC 2.2% 1,330,710 +3.1% 0% $20,439,706
TWO SIGMA INVESTMENTS, LP 2% 1,207,250 +940% 0.01% $18,543,360
GEODE CAPITAL MANAGEMENT, LLC 2% 1,204,150 +5% 0% $18,499,798
CITADEL ADVISORS LLC 2% 1,200,737 +241% 0.01% $18,443,321
ALGERT GLOBAL LLC 1.8% 1,110,889 +151% 0.2% $17,063,255
D. E. Shaw & Co., Inc. 1.8% 1,096,509 +1014% 0.01% $16,842,378
GOLDMAN SACHS GROUP INC 1.6% 952,675 +58% 0% $14,633,088
BANK OF AMERICA CORP /DE/ 1.5% 910,460 +14% 0% $13,984,665
MORGAN STANLEY 1.4% 836,966 +19% 0% $12,855,801
Nantahala Capital Management, LLC 1.3% 809,914 0% 0.75% $12,440,279
Qube Research & Technologies Ltd 1.2% 702,057 +256% 0.01% $10,783,596
Squarepoint Ops LLC 0.88% 532,321 -12% 0.02% $8,176,451
ORBIMED ADVISORS LLC 0.87% 524,700 -47% 0.15% $8,059,392
MILLENNIUM MANAGEMENT LLC 0.84% 504,544 +30% 0.01% $7,749,796

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
21
Latest
Q2 2026
Rows shown
1-21 of 21
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q2 60,725,969 $932,420,447 +$84,600,524 $15.36 192
2026 Q1 59,586,416 $827,823,706 -$45,211,811 $13.90 188
2025 Q4 62,149,272 $857,685,977 -$103,940,615 $13.80 173
2025 Q3 65,065,945 $1,590,036,358 -$3,819,977 $24.44 170
2025 Q2 65,389,958 $1,510,522,459 -$28,053,981 $23.10 169
2025 Q1 66,482,175 $1,805,570,973 -$17,647,630 $27.00 179
2024 Q4 64,089,510 $3,430,809,553 +$1,001,839,547 $53.54 213
2024 Q3 45,621,730 $2,072,353,785 +$42,332,014 $45.43 158
2024 Q2 44,723,442 $1,873,142,325 +$107,659,314 $41.89 153
2024 Q1 42,327,541 $1,593,608,078 +$334,250,630 $37.65 118
2023 Q4 33,501,695 $359,539,970 -$17,204,195 $10.73 64
2023 Q3 35,112,124 $353,984,587 +$45,518,472 $10.08 57
2023 Q2 30,508,831 $362,117,070 -$408,523 $11.87 54
2023 Q1 30,541,873 $369,527,936 +$18,629,245 $12.10 48
2022 Q4 28,954,042 $381,308,644 -$7,758,264 $13.17 49
2022 Q3 29,548,436 $400,093,845 +$8,918,649 $13.54 45
2022 Q2 28,911,820 $352,963,471 +$6,297,905 $12.21 43
2022 Q1 28,388,419 $407,113,023 +$11,406,319 $14.34 46
2021 Q4 27,496,946 $541,627,745 +$19,103,067 $19.73 46
2021 Q3 26,499,088 $571,208,440 +$35,499,490 $21.63 44
2021 Q2 24,743,225 $614,460,000 +$614,460,000 $24.95 29
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .